Table 7.

Main AEs’ rates (for grades 1–5) in present series compared to literature data on BZB and TH in oncology (or other) settings

	Present study %	Literature [64–72] %
Bevacizumab
Hypertension	7.2	5–19
Bleeding	2.8	1.7–6.7
Proteinuria	2.8	0.7–7.4
Arterial thromboembolism	1.4	0.7–4.4
Peripheral neuropathy	Not described	6.3
Thalidomide
Somnolence/drowsiness	16	2–23
Peripheral neuropathy	17.9	1–44
Thromboembolic event	2.9	1–6
Cardiac failure	1.4	1–8
Bleeding	1.4	Not described